- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
PRM
LSE
Week ended 07 Aug 2026
Weekly Investor Report
Proteome Sciences plc · Healthcare · Diagnostics & Research
Latest close
0.02 GBP
0.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 1.5% above the Trend Line and sits at 18.7% of its 52-week range. The latest completed week returned 0.0%, after a 5.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
27
out of 100
Latest Close
0.02 GBP
7 Aug 2026
1W Return
0.0%
latest completed week
4W Return
5.9%
short-term follow-through
12W Return
5.9%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
0.4x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 36.78% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.0%
Latest completed week; four-week move 5.9%.
Indicator stack
0/74
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 36.78%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
2 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 1.5% above the Trend Line and sits at 18.7% of its 52-week range. The latest completed week returned 0.0%, after a 5.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1112-week average 0.05
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.11Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 5.9% over four weeks, 5.9% over 12 weeks, and -38.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.86Latest activity-pressure read.
Pressure change111.9%Four-week change in activity pressure.
Leadership-18.83Latest relative-leadership reading.
RS change24.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 67%
Model confidence 53%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength33/100Blend of value, momentum, and quality. Underlying universe rank 68; rank 1 is best.
Value38/100Relative valuation strength. Underlying universe rank 63; rank 1 is best.
Quality39/100Profitability and accounting quality. Underlying universe rank 62; rank 1 is best.
Momentum39/100Medium-term price momentum. Underlying universe rank 62; rank 1 is best.
Growth39/100Revenue and earnings growth. Underlying universe rank 62; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.0x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -1.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- -2.2% Gross profit retained from each unit of revenue.
- Operating margin
- -71.0% Operating profit retained from revenue.
- Free-cash-flow margin
- -3.8% Free cash flow generated from revenue.
- Return on invested capital
- -36.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -23.1% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -8.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 2 relevant articles.
0 positive · 2 neutral · 0 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-59.1%Distance below the 52-week high.
13-week volatility9.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher7 of 2615 weeks finished lower.
Best week+21.7%Week of 1 May.
Worst week-16.7%Week of 8 May.
Latest week+0.0%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains0
Flat weeks4
Modest losses7
Sharp losses8
Recent vol9.6%13-week weekly-return volatility.
Base vol16.0%52-week weekly-return volatility.
Up/down split20/27Count of positive and negative weeks in the 52-week window.
Average skew14.3% / -9.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank22 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Diagnostics & Research
4-week rank3 / 10
Group average-2.7%
Trend breadth30.0%
Trend30.0%active weekly trend signals
MD20.0%positive activity pressure
RS20.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape21/100
Trend, activity pressure, participation, and risk combine to a 21/100 tape read.
Indicator analysis29/100Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.
Activity pressure 0.11; No reversal markers Next-Week ExpectancyNegative 36.78%Next-week expectancy is negative with a 36.78% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors36/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 64 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment50/100Weighted news tone is neutral across 2 relevant articles.
Proteome Sciences Secures New Chemoproteomics Contract Ahead of Planned 2026 Clinical Programme (PRM) Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.02 GBP | 0.0% | 0.02 GBP | 0.03 GBP | 0.86 | -18.83 | 681.5K | Off |
| 31 Jul 2026 | 0.02 GBP | 0.0% | 0.02 GBP | 0.03 GBP | 0.83 | -19.77 | 334.5K | Off |
| 24 Jul 2026 | 0.02 GBP | -5.3% | 0.02 GBP | 0.03 GBP | 0.70 | -20.05 | 566.3K | Off |
| 17 Jul 2026 | 0.02 GBP | 11.8% | 0.02 GBP | 0.03 GBP | 0.61 | -15.80 | 1.4M | Off |
| 10 Jul 2026 | 0.02 GBP | 4.6% | 0.02 GBP | 0.03 GBP | 0.41 | -25.00 | 2.1M | Off |
| 3 Jul 2026 | 0.02 GBP | -5.2% | 0.02 GBP | 0.04 GBP | 0.25 | -30.63 | 350.3K | Off |
| 26 Jun 2026 | 0.02 GBP | 13.6% | 0.02 GBP | 0.04 GBP | 0.24 | -26.83 | 6.9K | Off |
| 19 Jun 2026 | 0.02 GBP | -2.6% | 0.02 GBP | 0.04 GBP | 0.17 | -35.69 | 5.6K | Off |
| 12 Jun 2026 | 0.02 GBP | -3.1% | 0.02 GBP | 0.04 GBP | 0.18 | -35.77 | 3.7K | Off |
| 5 Jun 2026 | 0.02 GBP | 14.3% | 0.02 GBP | 0.04 GBP | 0.30 | -34.30 | 2.0M | Off |
| 29 May 2026 | 0.01 GBP | -6.7% | 0.02 GBP | 0.04 GBP | 0.06 | -43.77 | 7.3M | Off |
| 22 May 2026 | 0.01 GBP | -11.8% | 0.02 GBP | 0.04 GBP | -0.11 | -41.25 | 2.3M | Off |
| 15 May 2026 | 0.02 GBP | 21.4% | 0.02 GBP | 0.04 GBP | -0.35 | -32.95 | 3.4M | Off |
| 8 May 2026 | 0.01 GBP | -16.7% | 0.02 GBP | 0.04 GBP | -0.67 | -46.07 | 969.8K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.